U.S. markets close in 6 hours 22 minutes
  • S&P 500

    -27.87 (-0.65%)
  • Dow 30

    -142.06 (-0.42%)
  • Nasdaq

    -138.08 (-1.07%)
  • Russell 2000

    +13.42 (+0.68%)
  • Crude Oil

    0.00 (0.00%)
  • Gold

    -1.00 (-0.06%)
  • Silver

    -0.29 (-1.48%)

    -0.0036 (-0.35%)
  • 10-Yr Bond

    +0.0870 (+3.02%)

    -0.0106 (-0.89%)

    +1.0930 (+0.80%)

    -1,979.21 (-8.42%)
  • CMC Crypto 200

    -31.40 (-5.80%)
  • FTSE 100

    +23.61 (+0.31%)
  • Nikkei 225

    -11.77 (-0.04%)

Great news for Alpine Immune Sciences, Inc. (NASDAQ:ALPN): Insiders acquired stock in large numbers last year

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like they did in the case of Alpine Immune Sciences, Inc. (NASDAQ:ALPN), that sends out a positive message to the company's shareholders.

While insider transactions are not the most important thing when it comes to long-term investing, logic dictates you should pay some attention to whether insiders are buying or selling shares.

See our latest analysis for Alpine Immune Sciences

Alpine Immune Sciences Insider Transactions Over The Last Year

The insider, James Rickey, made the biggest insider sale in the last 12 months. That single transaction was for US$237k worth of shares at a price of US$13.92 each. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. The silver lining is that this sell-down took place above the latest price (US$9.27). So it may not shed much light on insider confidence at current levels. James Rickey was the only individual insider to sell over the last year.

Happily, we note that in the last year insiders paid US$268k for 26.90k shares. But insiders sold 17.01k shares worth US$237k. In the last twelve months there was more buying than selling by Alpine Immune Sciences insiders. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!


There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).

Insider Ownership

For a common shareholder, it is worth checking how many shares are held by company insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Our data suggests Alpine Immune Sciences insiders own 1.5% of the company, worth about US$4.2m. I generally like to see higher levels of ownership.

So What Do The Alpine Immune Sciences Insider Transactions Indicate?

It doesn't really mean much that no insider has traded Alpine Immune Sciences shares in the last quarter. On a brighter note, the transactions over the last year are encouraging. The transactions are fine but it'd be more encouraging if Alpine Immune Sciences insiders bought more shares in the company. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. Be aware that Alpine Immune Sciences is showing 4 warning signs in our investment analysis, and 1 of those shouldn't be ignored...

But note: Alpine Immune Sciences may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.